‘‘(28) Alpha-pyrrolidinopropiophenone (alpha- 
PPP). 
‘‘(29) 4-methoxy-alpha-pyrrolidinopropiophenone 
(MOPPP). 
‘‘(30) 
3,4-methylenedioxy-alpha- 
pyrrolidinopropiophenone (MDPPP). 
‘‘(31) Alpha-pyrrolidinovalerophenone (alpha- 
PVP). 
‘‘(32) 
6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol- 
6-amine) (MDAI). 
‘‘(33) 3-fluoromethcathinone. 
‘‘(34) 
4’-Methyl-α-pyrrolidinobutiophenone 
(MPBP).’’. 
SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT 
HAZARDS TO PUBLIC SAFETY EXPANSION. 
Section 201(h)(2) of the Controlled Substances Act (21 
U.S.C. 811(h)(2)) is amended— 
(1) by striking ‘‘one year’’ and inserting ‘‘2 
years’’; and 
(2) by striking ‘‘six months’’ and inserting ‘‘1 
year’’. 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Synthetic 
Drug Control Act of 2011’’. 
VerDate Mar 15 2010 
22:36 Nov 22, 2011
Jkt 019200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6202
E:\BILLS\H1254.RH
H1254
mstockstill on DSK4VPTVN1PROD with BILLS
SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I 
OF THE CONTROLLED SUBSTANCES ACT. 
(a) CANNABIMIMETIC AGENTS.—Schedule I, 
as set forth in section 202(c) of the Controlled 
Substances Act (21 U.S.C. 812(c)) is amended 
by adding at the end the following: 
‘‘(d)(1) Unless specifically exempted or un-
less listed in another schedule, any material, 
compound, mixture, or preparation which 
contains any quantity of cannabimimetic 
agents, or which contains their salts, isomers, 
and salts of isomers whenever the existence 
of such salts, isomers, and salts of isomers is 
possible within the specific chemical designa-
tion. 
‘‘(2) In paragraph (1): 
‘‘(A) 
The 
term 
‘cannabimimetic 
agents’ means any substance that is a 
cannabinoid receptor type 1 (CB1 recep-
tor) agonist as demonstrated by binding 
studies and functional assays within any 
of the following structural classes: 
‘‘(i) 2-(3-hydroxycyclohexyl)phenol 
with substitution at the 5-position of 
the phenolic ring by alkyl or alkenyl, 
VerDate Mar 15 2010 
22:36 Nov 22, 2011
Jkt 019200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6202
E:\BILLS\H1254.RH
H1254
mstockstill on DSK4VPTVN1PROD with BILLS
whether or not substituted on the 
cyclohexyl ring to any extent. 
‘‘(ii) 3-(1-naphthoyl)indole or 3-(1- 
naphthylmethane)indole 
by 
substi-
tution at the nitrogen atom of the 
indole ring, whether or not further 
substituted on the indole ring to any 
extent, whether or not substituted on 
the naphthoyl or naphthyl ring to any 
extent. 
‘‘(iii) 
3-(1-naphthoyl)pyrrole 
by 
substitution at the nitrogen atom of 
the pyrrole ring, whether or not fur-
ther substituted in the pyrrole ring to 
any extent, whether or not sub-
stituted on the naphthoyl ring to any 
extent. 
‘‘(iv) 
1-(1- 
naphthylmethylene)indene by substi-
tution of the 3-position of the indene 
ring, whether or not further sub-
stituted in the indene ring to any ex-
tent, whether or not substituted on 
the naphthyl ring to any extent. 
VerDate Mar 15 2010 
22:36 Nov 22, 2011
Jkt 019200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6202
E:\BILLS\H1254.RH
H1254
mstockstill on DSK4VPTVN1PROD with BILLS
‘‘(v) 3-phenylacetylindole or 3- 
benzoylindole by substitution at the 
nitrogen atom of the indole ring, 
whether or not further substituted in 
the indole ring to any extent, whether 
or not substituted on the phenyl ring 
to any extent. 
‘‘(B) Such term includes— 
‘‘(i) 
5-(1,1-dimethylheptyl)-2- 
[(1R,3S)-3-hydroxycyclohexyl]-phenol 
(CP–47,497); 
‘‘(ii) 
5-(1,1-dimethyloctyl)-2- 
[(1R,3S)-3-hydroxycyclohexyl]-phenol 
(cannabicyclohexanol 
or 
CP–47,497 
C8-homolog); 
‘‘(iii) 
1-pentyl-3-(1-naph-
thoyl)indole (JWH–018 and AM678); 
‘‘(iv) 1-butyl-3-(1-naphthoyl)indole 
(JWH–073); 
‘‘(v) 1-hexyl-3-(1-naphthoyl)indole 
(JWH–019); 
‘‘(vi) 
1-[2-(4-morpholinyl)ethyl]-3- 
(1-naphthoyl)indole (JWH–200); 
VerDate Mar 15 2010 
22:36 Nov 22, 2011
Jkt 019200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6202
E:\BILLS\H1254.RH
H1254
mstockstill on DSK4VPTVN1PROD with BILLS
‘‘(vii) 
1-pentyl-3-(2- 
methoxyphenylacetyl)indole 
(JWH– 
250); 
‘‘(viii) 
1-pentyl-3-[1-(4- 
methoxynaphthoyl)]indole (JWH–081); 
‘‘(ix) 
1-pentyl-3-(4-methyl-1-naph-
thoyl)indole (JWH–122); 
‘‘(x) 
1-pentyl-3-(4-chloro-1-naph-
thoyl)indole (JWH–398); 
‘‘(xi) 
1-(5-fluoropentyl)-3-(1-naph-
thoyl)indole (AM2201); 
‘‘(xii) 
1-(5-fluoropentyl)-3-(2- 
iodobenzoyl)indole (AM694); 
‘‘(xiii) 1-pentyl-3-[(4-methoxy)-ben-
zoyl]indole (SR–19 and RCS–4); 
‘‘(xiv) 
1-cyclohexylethyl-3-(2- 
methoxyphenylacetyl)indole 
(SR–18 
and RCS–8); and 
‘‘(xv) 
1-pentyl-3-(2- 
chlorophenylacetyl)indole 
(JWH– 
203).’’. 
(b) OTHER DRUGS.—Schedule I of section 
202(c) of the Controlled Substances Act (21 
U.S.C. 812(c)) is amended in subsection (c) by 
adding at the end the following: 
VerDate Mar 15 2010 
22:36 Nov 22, 2011
Jkt 019200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6202
E:\BILLS\H1254.RH
H1254
mstockstill on DSK4VPTVN1PROD with BILLS
‘‘(18) 
4-methylmethcathinone 
(Mephedrone). 
‘‘(19) 3,4-methylenedioxypyrovalerone 
(MDPV). 
‘‘(20) 
3,4- 
methylenedioxymethcathinone 
(methylone). 
‘‘(21) 
Naphthylpyrovalerone 
(naphyrone). 
‘‘(22) 
4-fluoromethcathinone 
(flephedrone). 
‘‘(23) 
4-methoxymethcathinone 
(methedrone; Bk–PMMA). 
‘‘(24) 
Ethcathinone 
(N- 
Ethylcathinone). 
‘‘(25) 3,4-methylenedioxyethcathinone 
(ethylone). 
‘‘(26) 
Beta-keto-N-methyl-3,4- 
benzodioxyolybutanamine (butylone). 
‘‘(27) 
N,N-dimethylcathinone 
(metamfepramone). 
‘‘(28) 
Alpha- 
pyrrolidinopropiophenone (alpha-PPP). 
‘‘(29) 
4-methoxy-alpha- 
pyrrolidinopropiophenone (MOPPP). 
VerDate Mar 15 2010 
22:36 Nov 22, 2011
Jkt 019200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6202
E:\BILLS\H1254.RH
H1254
mstockstill on DSK4VPTVN1PROD with BILLS
‘‘(30) 
3,4-methylenedioxy- 
alphapyrrolidinopropiophenone 
(MDPPP). 
‘‘(31) Alpha-pyrrolidinovalerophenone 
(alpha-PVP). 
‘‘(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3- 
dioxol-6-amine) (MDAI). 
‘‘(33) 3-fluoromethcathinone. 
‘‘(34) 
4’-Methyl-α- 
pyrrolidinobutiophenone (MPBP). 
‘‘(35) 
2-(2,5-Dimethoxy-4- 
ethylphenyl)ethanamine (2C–E). 
‘‘(36) 
2-(2,5-Dimethoxy-4- 
methylphenyl)ethanamine (2C–D). 
‘‘(37) 
2-(4-Chloro-2,5- 
dimethoxyphenyl)ethanamine (2C–C). 
‘‘(38) 
2-(4-Iodo-2,5- 
dimethoxyphenyl)ethanamine (2C–I). 
‘‘(39) 
2-[4-(Ethylthio)-2,5- 
dimethoxyphenyl]ethanamine (2C–T–2). 
‘‘(40) 
2-[4-(Isopropylthio)-2,5- 
dimethoxyphenyl]ethanamine (2C–T–4). 
‘‘(41) 
2-(2,5- 
Dimethoxyphenyl)ethanamine (2C–H). 
VerDate Mar 15 2010 
22:36 Nov 22, 2011
Jkt 019200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6202
E:\BILLS\H1254.RH
H1254
mstockstill on DSK4VPTVN1PROD with BILLS
‘‘(42) 
2-(2,5-Dimethoxy-4-nitro- 
phenyl)ethanamine (2C–N). 
‘‘(43) 
2-(2,5-Dimethoxy-4-(n)- 
propylphenyl)ethanamine (2C–P).’’. 
SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT 
HAZARDS TO PUBLIC SAFETY EXPANSION. 
Section 201(h)(2) of the Controlled Sub-
stances Act (21 U.S.C. 811(h)(2)) is amended— 
(1) by striking ‘‘one year’’ and insert-
ing ‘‘2 years’’; and 
(2) by striking ‘‘six months’’ and in-
serting ‘‘1 year’’. 
VerDate Mar 15 2010 
22:36 Nov 22, 2011
Jkt 019200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6202
E:\BILLS\H1254.RH
H1254
mstockstill on DSK4VPTVN1PROD with BILLS
VerDate Mar 15 2010 
22:36 Nov 22, 2011
Jkt 019200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6202
E:\BILLS\H1254.RH
H1254
mstockstill on DSK4VPTVN1PROD with BILLS
Union Calendar No. 196 
112TH CONGRESS 
1ST SESSION 
H. R. 1254 
[Report No. 112–295, Parts I and II] 
A BILL 
To amend the Controlled Substances Act to place 
synthetic drugs in Schedule I. 
NOVEMBER 22, 2011 
Reported from the Committee on Energy and Commerce 
with an amendment 
NOVEMBER 22, 2011 
Reported from the Committee on the Judiciary with an 
amendment, committed to the Committee of the Whole 
House on the State of the Union, and ordered to be 
printed 
VerDate Mar 15 2010 
22:36 Nov 22, 2011
Jkt 019200
PO 00000
Frm 00016
Fmt 6651
Sfmt 6651
E:\BILLS\H1254.RH
H1254
mstockstill on DSK4VPTVN1PROD with BILLS